Fecal calprotectin in inflammatory bowel disease
暂无分享,去创建一个
[1] R. Sherwood,et al. Fecal calprotectin in inflammatory bowel disease , 2016, Clinical and experimental gastroenterology.
[2] Steven J Brown,et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. , 2015, Gastroenterology.
[3] E. Cabré,et al. High Within-day Variability of Fecal Calprotectin Levels in Patients with Active Ulcerative Colitis: What Is the Best Timing for Stool Sampling? , 2015, Inflammatory bowel diseases.
[4] E. Cotte,et al. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease , 2015, The American Journal of Gastroenterology.
[5] David C. Wilson,et al. Faecal Calprotectin in Suspected Paediatric Inflammatory Bowel Disease , 2015, Journal of pediatric gastroenterology and nutrition.
[6] Takayuki Yamamoto. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease , 2015, United European gastroenterology journal.
[7] C. Beglinger,et al. Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis , 2015, Digestive Diseases and Sciences.
[8] Christoph Beglinger,et al. The role and utility of faecal markers in inflammatory bowel disease , 2015, Therapeutic advances in gastroenterology.
[9] G. Rogler,et al. Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead ‘Optimised Monitoring' Recommendations , 2014, Digestion.
[10] A. Ristimäki,et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? , 2014, Journal of Crohn's & colitis.
[11] L. Öhman,et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. , 2014, Journal of Crohn's & colitis.
[12] P. Henderson,et al. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.
[13] C. Beglinger,et al. Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness , 2014, BMC Gastroenterology.
[14] M. Kiszka-Kanowitz,et al. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment , 2014, Scandinavian journal of gastroenterology.
[15] G. D'Haens,et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease , 2014, United European gastroenterology journal.
[16] T. Lobaton,et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. , 2013, Journal of Crohn's & colitis.
[17] J. Belaiche,et al. Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy , 2013, Inflammatory bowel diseases.
[18] P. Pavlidis,et al. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care , 2013, Scandinavian journal of gastroenterology.
[19] Takayuki Yamamoto,et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study , 2013, United European gastroenterology journal.
[20] H. Nielsen,et al. Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis , 2013, Scandinavian journal of gastroenterology.
[21] A. Schoepfer,et al. Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.
[22] A. Morris,et al. A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent Crohn's disease , 2013, Alimentary pharmacology & therapeutics.
[23] R. Gama,et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits , 2013, Annals of clinical biochemistry.
[24] S. Vermeire,et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease , 2012, Inflammatory bowel diseases.
[25] Jing-Long Huang,et al. Fecal Calprotectin as a Correlative Marker in Clinical Severity of Infectious Diarrhea and Usefulness in Evaluating Bacterial or Viral Pathogens in Children , 2012, Journal of pediatric gastroenterology and nutrition.
[26] M. Färkkilä,et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF&agr; blocking agents , 2012, Inflammatory bowel diseases.
[27] R. Sherwood,et al. Faecal markers of gastrointestinal inflammation , 2012, Journal of Clinical Pathology.
[28] O. Dewit,et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. , 2012, Journal of Crohn's & colitis.
[29] N. D. de Wit,et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. , 2012, Clinical chemistry.
[30] A. Schoepfer,et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. , 2012, Journal of Crohn's & colitis.
[31] M. Huml,et al. Evaluation of faecal calprotectin as a valuable non‐invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis , 2010, Acta paediatrica.
[32] P. V. van Rheenen,et al. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis , 2010, BMJ : British Medical Journal.
[33] K. Kolho,et al. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease , 2010, Scandinavian journal of gastroenterology.
[34] J. Gisbert,et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? , 2010, Journal of Crohn's & colitis.
[35] M. Pakarinen,et al. Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric‐onset ulcerative colitis† , 2010, Inflammatory bowel diseases.
[36] I. Ayadi,et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study , 2010, European journal of gastroenterology & hepatology.
[37] H. Tilg,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.
[38] C. Geczy,et al. ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS. , 2009, Anti-inflammatory & anti-allergy agents in medicinal chemistry.
[39] J. Mate,et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.
[40] M. Mohiuddin,et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease , 2009, The British journal of surgery.
[41] H. Drummond,et al. Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis , 2009, The American Journal of Gastroenterology.
[42] L. Maiden. Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy , 2009, Journal of Gastroenterology.
[43] M. Färkkilä,et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease , 2008, Inflammatory bowel diseases.
[44] M. Castro,et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases , 2008, Inflammatory bowel diseases.
[45] R. D'Incà,et al. Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.
[46] S. Kugathasan,et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[47] A. Forbes,et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis , 2008, European journal of gastroenterology & hepatology.
[48] A. Michalsen,et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.
[49] M. Färkkilä,et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.
[50] A. Darzi,et al. Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.
[51] R. D'Incà,et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[52] T. Raivio,et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease , 2006, Scandinavian journal of gastroenterology.
[53] M. Bottai,et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.
[54] M. Vatn,et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT) , 2004, Gut.
[55] I. Forgacs,et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.
[56] M. Fagerhol,et al. Age-dependent variations in fecal calprotectin concentrations in children. , 2002, Journal of pediatric gastroenterology and nutrition.
[57] I. Bjarnason,et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma , 2001, Gut.
[58] E. Husebye,et al. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm , 2001, American Journal of Gastroenterology.
[59] I. Bjarnason,et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.
[60] A. Price,et al. Assessment of ileal pouch inflammation by single-stool calprotectin assay , 2000, Diseases of the colon and rectum.
[61] A. Røseth,et al. High prevalence of NSAID enteropathy as shown by a simple faecal test , 1999, Gut.
[62] Clinique La Source-Baulieu. Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead 'Optimised Monitoring' Recommendations , 2016 .
[63] Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel , 2012 .
[64] M. Picco. Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010 .
[65] J. Gisbert,et al. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[66] F. Castiglione,et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. , 2006, European review for medical and pharmacological sciences.
[67] A. Røseth,et al. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.
[68] J. Jahnsen,et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.
[69] I. Dale,et al. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. , 1980, Bulletin europeen de physiopathologie respiratoire.
[70] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.